Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$3,572 Mln
Revenue (TTM)
$37 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2
Industry P/E
--
EV/EBITDA
14.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-4.5
Face value
--
Shares outstanding
86,363,696
CFO
$-565.84 Mln
EBITDA
$-1,028.68 Mln
Net Profit
$-997.30 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Crispr Therapeutics AG (CRSP)
| 5.6 | 14.5 | -1.3 | -34.6 | -12.8 | -7.8 | -- |
|
BSE Sensex*
| 4.3 | -0.9 | 10.5 | 6.0 | 16.6 | 19.4 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Crispr Therapeutics AG (CRSP)
| 54.0 | -46.4 | -50.5 | 151.4 | 113.2 | 21.5 | 15.9 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Crispr Therapeutics AG (CRSP)
|
41.6 | 3,572.0 | 37.0 | -385.7 | -1,282.9 | -20.5 | -- | 2.0 |
| 1.9 | 195.8 | 28.3 | -52.1 | -183.5 | -46.3 | -- | 1.7 | |
| 3.4 | 355.2 | 70.2 | -149.8 | -104.3 | -- | -- | 2.6 | |
| 0.1 | 2.9 | 7.0 | -8.5 | -181.4 | -- | -- | 5.0 |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The... company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. Read more
CEO & Chairman
Dr. Samarth Kulkarni Ph.D.
CEO & Chairman
Dr. Samarth Kulkarni Ph.D.
Headquarters
Zug
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Crispr Therapeutics AG (CRSP) stood at $ 2,286 Mln as on 31-Mar-25
The share price of Crispr Therapeutics AG (CRSP) is $41.58 (NASDAQ) as of 16-Jun-2025 16:00 EDT. Crispr Therapeutics AG (CRSP) has given a return of -12.78% in the last 3 years.
Crispr Therapeutics AG (CRSP) has a market capitalisation of $ 3,572 Mln as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Crispr Therapeutics AG (CRSP) is 1.95 times as on 13-Jun-2025, a 24% discount to its peers’ median range of 2.58 times.
Since, TTM earnings of Crispr Therapeutics AG (CRSP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Crispr Therapeutics AG (CRSP) and enter the required number of quantities and click on buy to purchase the shares of Crispr Therapeutics AG (CRSP).
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
The CEO & director of Dr. Samarth Kulkarni Ph.D.. is Crispr Therapeutics AG (CRSP), and CFO & Sr. VP is Dr. Samarth Kulkarni Ph.D..
There is no promoter pledging in Crispr Therapeutics AG (CRSP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
31
|
|
|
21
|
|
|
1
|
|
|
31
|
|
|
21
|
|
|
1
|
| Crispr Therapeutics AG (CRSP) | Ratios |
|---|---|
|
Return on equity(%)
|
-20.47
|
|
Operating margin(%)
|
-1282.89
|
|
Net Margin(%)
|
-1042.77
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Crispr Therapeutics AG (CRSP) was $0 Mln.
$0.22
(
